Patient characteristics of 3 independent pAML cohorts with St. Jude AML02, COG’s TARGET-0531, and COG’s TARGET-1031 clinical cohorts
| Ped-AML with only ADE . | AML02 (N = 163) . | TARGET-0531 (N = 201) . | TARGET-1031 (N = 411) . | P value∗ . |
|---|---|---|---|---|
| Age, median (range) | 9.3 (0.0-21.2) | 10.1 (0.1-20.4) | 10.0 (0.1-29.6) | .14 |
| Sex, n/N (%) | .37 | |||
| Female | 74/163 (45%) | 105/201 (52%) | 194/411 (47%) | |
| Male | 89/163 (55%) | 96/201 (48%) | 217/411 (53%) | |
| Race, n/N (%) | .023 | |||
| White | 115/162 (71%) | 150/201 (75%) | 296/409 (72%) | |
| Black | 31/162 (19%) | 17/201 (8.5%) | 52/409 (13%) | |
| Other/Unknown | 16/162 (9.9%) | 34/201 (17%) | 61/409 (15%) | |
| Risk group, n/N (%) | <.001 | |||
| Low | 55/163 (34%) | 90/196 (46%) | 165/405 (41%) | |
| Standard | 65/163 (40%) | 76/196 (39%) | 231/405 (57%) | |
| High | 43/163 (26%) | 30/196 (15%) | 9/405 (2.2%) |
| Ped-AML with only ADE . | AML02 (N = 163) . | TARGET-0531 (N = 201) . | TARGET-1031 (N = 411) . | P value∗ . |
|---|---|---|---|---|
| Age, median (range) | 9.3 (0.0-21.2) | 10.1 (0.1-20.4) | 10.0 (0.1-29.6) | .14 |
| Sex, n/N (%) | .37 | |||
| Female | 74/163 (45%) | 105/201 (52%) | 194/411 (47%) | |
| Male | 89/163 (55%) | 96/201 (48%) | 217/411 (53%) | |
| Race, n/N (%) | .023 | |||
| White | 115/162 (71%) | 150/201 (75%) | 296/409 (72%) | |
| Black | 31/162 (19%) | 17/201 (8.5%) | 52/409 (13%) | |
| Other/Unknown | 16/162 (9.9%) | 34/201 (17%) | 61/409 (15%) | |
| Risk group, n/N (%) | <.001 | |||
| Low | 55/163 (34%) | 90/196 (46%) | 165/405 (41%) | |
| Standard | 65/163 (40%) | 76/196 (39%) | 231/405 (57%) | |
| High | 43/163 (26%) | 30/196 (15%) | 9/405 (2.2%) |
Kruskal-Wallis rank-sum test; Pearson χ2 test.